Similar articles

• Rosuvastatin in patients with elevated C-reactive protein.

  Chan PS, Nallamothu BK, Hayward RA. Chan PS, et al. N Engl J Med. 2009 Mar 5;360(10):1039; author reply 1041-2. N Engl J Med. 2009. PMID: 19271273 No abstract available.
• Rosuvastatin in patients with elevated C-reactive protein.

  Koller MT, Bucher HC, Steyerberg EW. Koller MT, et al. N Engl J Med. 2009 Mar 5;360(10):1041; author reply 1041-2. N Engl J Med. 2009. PMID: 19271276 No abstract available.
• JUPITER study highlights value of anti-inflammatory action of rosuvastatin.

  [No authors listed] [No authors listed] Cardiovasc J Afr. 2009 May-Jun;20(3):211. Cardiovasc J Afr. 2009. PMID: 19575096 No abstract available.
• [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].

  Olsson AG. Olsson AG. Lakartidningen. 2009 May 20-Jun 2;106(21-22):1471-5. Lakartidningen. 2009. PMID: 19579435 Review. Swedish. No abstract available.
• Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

  Ridker PM; JUPITER Study Group. Ridker PM, et al. Circulation. 2003 Nov 11;108(19):2292-7. doi: 10.1161/01.CIR.0000100688.17280.E6. Circulation. 2003. PMID: 14609996 Review. No abstract available.